The global microRNA market size is expected to reach USD 5.37 billion by 2032, expected to grow at a CAGR of 11.4% during the forecast period.
MicroRNA (miRNA) is a class of small, non-coding RNA molecules that play crucial roles in regulating gene expression. Their ability to influence numerous biological processes, including cell development, proliferation, and apoptosis, has made them a central focus in medical research. miRNAs are also associated with the development of various diseases, including cancers, cardiovascular disorders, neurological diseases, and autoimmune conditions.
Research Scope
The research scope in the microRNA market covers a wide array of areas, including:
- Identification of New miRNA Biomarkers
- Researchers are focusing on identifying new miRNAs that are involved in disease pathways, which could serve as diagnostic or prognostic biomarkers for diseases such as cancer, neurological disorders, and autoimmune diseases.
- Development of miRNA-Based Therapies
- A key area of research is the development of miRNA mimics and inhibitors that can modulate the expression of genes involved in disease processes. Clinical trials are underway to test the efficacy of miRNA-based therapeutics in treating various diseases.
- miRNA Delivery Systems
- A significant challenge in miRNA-based therapies is delivering miRNA molecules effectively to target cells. Research into nanoparticle-based delivery systems and other novel delivery methods is a critical area of investigation.
Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/microrna-market/request-for-sample
The major global market players include:
- Biodynamics Laboratory Inc.
- BioGenex, Horizon Discovery
- GeneCopoeia
- Merck KgaA
- Miltenyi Biotec
- NanoString
- New England Biolabs
- OriGene Technologies
Challenges in the Market
- Regulatory and Ethical Concerns
- miRNA-based therapeutics are subject to regulatory hurdles, and their clinical development must adhere to rigorous safety and ethical guidelines, particularly in gene editing and therapy.
- Delivery Challenges
- Efficient delivery of miRNA molecules to specific target tissues remains a major challenge. Research is ongoing to develop effective delivery mechanisms that can overcome barriers such as cellular uptake and immune system response.
- High Costs of Development
- The cost of developing miRNA-based therapies, including the discovery of novel miRNAs and the development of effective delivery systems, remains a significant barrier to market growth.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
MicroRNA, Products Outlook (Revenue – USD Billion, 2019-2032)
- Instrument
- Consumables
MicroRNA, Services Outlook (Revenue – USD Billion, 2019-2032)
- Service Type
- Isolation & Purification
- miRNA cDNA Synthesis
- Profiling, Localization, & Quantification
- Functional Analysis
- Others
- Specimen
- Whole Blood
- Serum
- Plasma
- FFPE
- Fresh Frozen Tissue
- Others
MicroRNA, Application Outlook (Revenue – USD Billion, 2019-2032)
- Cancer
- Infectious Diseases
- Immunological Disorder
- Cardiovascular Disease
- Neurological Disease
- Others
Recent Developments
- In November 2019, Novartis made a significant acquisition by purchasing The Medicines Company for USD 9.7 billion. This strategic move enables Novartis to enhance its therapeutic pipeline further. The addition includes a promising siRNA and miRNA inhibitor that has the potential to revolutionize the treatment of elevated low-density lipoprotein cholesterol (LDL-C) in high-risk patients. This acquisition aligns with Novartis’ goal of expanding its portfolio and advancing innovative therapies in key therapeutic areas.
- In May 2019, Thermo Fisher Scientific and Scinogy partnered to expedite the commercialization of MicroRNA and other cell and gene therapies. This collaboration brings together the expertise and resources of both companies to accelerate the development and availability of these advanced therapies.
- In February 2022, a team of researchers at the University of Illinois Urbana made a breakthrough by developing a novel point-of-care test for cancer detection using microRNAs (miRNAs). This innovative test utilizes nanoparticles to capture tumor-specific miRNAs present in human serum.
The microRNA market is poised for significant growth, driven by advancements in genomic research, increasing demand for personalized medicine, and the growing application of miRNAs in diagnostics and therapeutics. With the potential to revolutionize the treatment of chronic and complex diseases, the miRNA market is an exciting area of innovation in biotechnology and healthcare.